Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

Joe J. Stephenson, John Nemunaitis, Anil A. Joy, Julie C. Martin, Ying Ming Jou, Da Zhang, Paul Statkevich, Siu Long Yao, Yali Zhu, Honghong Zhou, Karen Small, Rajat Bannerji, Martin J. Edelman

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences